原发性脊髓胶质母细胞瘤:单中心患者回顾性研究
该单中心回顾性研究纳入2008至2014年间在华西医院接受手术切除的14例原发性脊髓胶质母细胞瘤患者,中位随访15个月,中位总生存期15个月、中位无进展生存期8个月。单因素分析显示年龄和术后放疗与总生存期及无进展生存期显著相关,术前Karnofsky功能状态评分仅影响总生存期。作者认为术后放疗联合替莫唑胺化疗可改善预后,可能作为可行的术后辅助治疗。
要点
- 14例原发性脊髓胶质母细胞瘤患者中位总生存期15个月,中位无进展生存期8个月。
- 单因素分析显示年龄与术后放疗均与总生存期和无进展生存期显著相关。
- 作者认为术后放疗联合替莫唑胺化疗可改善预后,可能作为可行的术后辅助治疗。
核心结论
- 作者认为,术后放疗联合替莫唑胺化疗可改善预后,可能作为原发性脊髓胶质母细胞瘤可行的术后辅助治疗。
研究设计与样本
- 单中心回顾性研究,纳入2008年至2014年间在华西医院接受手术切除的14例原发性脊髓胶质母细胞瘤患者,记录人口学、手术和术后因素,采用Kaplan-Meier法计算并比较总生存期和无进展生存期。
主要发现
- 8例男性(57%)和6例女性(43%),中位年龄28岁(范围14-56岁),中位Karnofsky功能状态评分60分(范围20-90分)。
- 4例(28.6%)接受全切除,5例(35.7%)部分切除,其余5例(35.7%)仅活检。
- 9例(64.3%)接受术后放疗和化疗,3例(21.4%)仅化疗,2例(14.3%)两者均未接受。
- 中位随访15个月(范围5-26个月),1年和2年生存率分别为78.5%(11/14)和7.1%(1/14),中位总生存期15个月,中位无进展生存期8个月。
- 单因素log-rank分析显示,总生存期和无进展生存期均与年龄显著相关(P=0.007和P=0.04),与术后放疗显著相关(P=0.001和P=0.002);术前Karnofsky功能状态评分仅影响总生存期(P=0.033),不影响无进展生存期(P=0.106)。
临床怎么用
- 作者认为,术后放疗联合替莫唑胺化疗可改善预后,可能作为原发性脊髓胶质母细胞瘤可行的术后辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Primary spinal cord (PSC) glioblastoma multiforme (GBM) is extremely rare and accounts for only 1.5% of all spinal cord tumors. Therefore, its treatment is still ill defined. To elucidate prognostic factors, we performed a single-institutional retrospective review of the largest series to date of patients with PSC GBM who underwent surgical resection in West China Hospital between 2008 and 2014. A total of 14 patients with PSC GBM were reviewed. METHODS: Demographic, operative, and postoperative factors were recorded. Overall survival (OS) and progression-free survival (PFS) were calculated and compared with the Kaplan-Meier method. RESULTS: Eight males (57%) and 6 females (43%) were involved in the study. Their median age was 28 years (range, 14-56 years). Median Karnofsky Performance Status score was 60 (range, 20-90). Four patients (28.6%) received gross total resection, 5 (35.7%) partial resection, and the remaining 5 (35.7%) biopsy only. Nine patients (64.3%) received postoperative radiotherapy and chemotherapy, 3 (21.4%) chemotherapy only, and 2 (14.3%) neither. Median follow-up period was 15 months (range, 5-26 months). One-year and 2-year survival was 78.5% (11/14) and 7.1% (1/14), respectively. Median OS was 15 months, and median PFS 8 months. Univariate log-rank analysis showed that OS and PFS were significantly associated with patients' age (P = 0.007 and P = 0.04, respectively) and postoperative radiotherapy (P = 0.001 and P = 0.002, respectively). However, preoperative Karnofsky Performance Status score affected only OS and did not affect PFS (P = 0.033 and P = 0.106, respectively). CONCLUSIONS: According to our study, the combination of postoperative radiotherapy and temozolomide chemotherapy can improve prognosis and may serve as a feasible postoperative adjuvant treatment of PSC GBM.
引用
- Cheng X, Lou S, Huang S, et al. Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution. World Neurosurg. 2017. PMID: 28377242. doi:10.1016/j.wneu.2017.03.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。